Verseon Nominates VE-4840 as Primary Drug Candidate for Oral Prophylaxis and Treatment of Diabetic Eye Disease
Precision-engineered by Verseon's unique
computational platform,
VE-4840 advances as primary development candidate after key in vivo
and preliminary toxicology studies